2026-01-23 - Analysis Report
**Financial Report for Regeneron Pharmaceuticals, Inc. (REGN)**

### Quick Overview

Regeneron Pharmaceuticals, Inc. is a biotechnology company specializing in the development and commercialization of innovative pharmaceutical products. The company focuses on creating medicines for difficult-to-treat diseases.

### Comparison with S&P 500 (VOO)

* Cumulative return of review stock: 29.18%
* Cumulative return of comparison stock (S&P 500, VOO): 92.53%
* Divergence: -67.90 (relative divergence: 20.10%)

Analysis: The cumulative return of REGN is lower than that of VOO, indicating a higher level of volatility. The company's return rate over the past 7 years has fluctuated between -14.0% and 55.0%, suggesting an unstable market presence.

### Alpha, Beta Analysis

| Year       | CAGR | MDD  | Alpha | Beta | Cap(B) |
|------------|------|------|-------|------|--------|
| 2016-2018  | -14.0% | 22.4% | -19.0% | 1.2 | 39.6B  |
| 2017-2019  | -3.0% | 28.6% | -21.0% | 1.0 | 39.8B  |
| 2018-2020  | 2.0% | 28.6% | -19.0% | 0.7 | 51.2B  |
| 2019-2021  | 29.0% | 28.6% | -15.0% | 0.6 | 66.9B  |
| 2020-2022  | 55.0% | 14.4% | 56.0% | 0.6 | 76.5B  |
| 2021-2023  | 46.0% | 14.4% | 45.0% | 0.6 | 93.1B  |
| 2022-2024  | -7.0% | 30.9% | -26.0% | 0.6 | 75.5B  |
| 2023-2025  | -4.0% | 45.4% | -66.0% | 0.6 | 81.8B  |

Analysis: The company's Capital has increased over the years, with a peak of $93.1B in 2024. The Alpha value fluctuates significantly, ranging from -19.0% to 56.0%. The Beta value also varies, ranging from 0.7 to 1.2, indicating varying levels of market sensitivity.

### Stock Price Fluctuations

* Close: $755.51
* Last-market: +0.82% ( price: 755.51, previousClose: 749.33, change: 0.82 )
* 5-day SMA: $742.72
* 20-day SMA: $770.03
* 60-day SMA: $729.47

Analysis: The stock has experienced a recent price fluctuation, with a 5-day SMA lower than the close price and a sharp rebound, indicating a possible fluctuation issue.

### Technical Indicators

* Market Risk Indicator (MRI): 0.90 (High Investment Recommended)
* RSI: 45.14
* PPO: -0.84
* Hybrid Signal: Buy (Cash 0%)
* Risk Level: High (MRI 0.90)
* 20 days relative divergence change: -8.10 (worsening)
* 7-day Rank change: 33 (rank up)
* 7-day Dynamic Expected Return change: -3.30 (worsening)
* Expected Return (%): -48.00%

Analysis: The stock has a High Investment Recommendation due to a high MRI score. The RSI is below 50, indicating a potential buy signal. However, the PPO is negative and the hybrid signal is also a buy, suggesting a contradiction in the technical indicators.

### Recent News & Significant Events

* Evercore ISI Group Raises Price Target to $875, Maintains Outperform Rating
* Universal Beteiligungs und Servicegesellschaft mbH Increases Position in Regeneron Pharmaceuticals, Inc. $REGN
* Regeneron Faces Neurology Leadership Shift As Investors Weigh Pipeline Execution

Analysis: The recent news indicates a mixed sentiment for the company, with analysts maintaining a positive outlook but investors being cautious due to the leadership shift.

### Analyst Opinions

* Analyst Consensus:
  - Key: Buy
  - Mean (1=StrongBuy~5=Sell): 1.69 (~Buy)
  - Opinions: 26
  - Target Price (avg/high/low): 830.04 / 1057.00 / 630.00

Analysis: The analyst consensus is neutral, with a mean rating of 1.69, which is close to the "Buy" rating.

### Earnings Analysis

| Date | EPS | Revenue |
|---|---:|---:|
| 2025-10-28 | 14.09 | 3.75 B$ |
| 2025-08-01 | 13.24 | 3.68 B$ |
| 2025-04-29 | 7.58 | 3.03 B$ |
| 2024-10-31 | 12.4 | 3.72 B$ |
| 2025-10-28 | 12.4 | 3.72 B$ |

Analysis: The company has reported stable revenue growth over the past 4 quarters, ranging from 3.03B$ to 3.75B$. The earnings per share (EPS) values also show stability, ranging from 7.58 to 14.09.

### Quarterly Financial Information

#### Revenue and Profitability

| Quarter | Revenue | Profit Margin |
|---------|----------|---------------|
| 2025-09-30 | $3.75B | 86.11% |
| 2025-06-30 | $3.68B | 85.58% |
| 2025-03-31 | $3.03B | 84.67% |
| 2024-12-31 | $3.79B | 85.08% |
| 2024-09-30 | $3.72B | 86.80% |

Analysis: The revenue and profit margin values are stable, indicating a consistent financial performance for the company.

#### Capital and Profitability

| Quarter | Equity | ROE |
|---------|---------|-----|
| 2025-09-30 | $30.96B | 4.72% |
| 2025-06-30 | $29.94B | 4.65% |
| 2025-03-31 | $29.39B | 2.75% |
| 2024-12-31 | $29.35B | 3.13% |
| 2024-09-30 | $29.33B | 4.57% |

Analysis: The equity values are stable, ranging from 29.33B$ to 30.96B$. The return on equity (ROE) values are also stable, ranging from 2.75% to 4.72%.

**Disclaimer:** This report is for informational purposes only and does not constitute financial advice. Investment involves risk.